Active Not RecruitingNCT03573349
Ketamine and brain chemistry changes in treatment-resistant depression
About this title
Read the official source — NCT03573349Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- RochesterSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 3, 2019
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 18
- Sponsor
- Mayo Clinic
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03573349
- Official title
Show the full official title
Central Versus Peripheral GABA and Glutamate Biomarkers for Treatment Response During Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Rochester
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mayo Clinic, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including ketamine.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
